Aytu Boston Consulting Group Matrix
See the Bigger Picture
Aytu’s BCG Matrix preview highlights where its core products may sit across Stars, Cash Cows, Dogs, and Question Marks, offering a quick read on growth potential and portfolio risks; the full report expands this into quadrant-level placements, market-share drivers, and prioritized strategic moves. Purchase the complete BCG Matrix for a detailed Word report plus an editable Excel summary that delivers data-backed recommendations, resource allocation guidance, and ready-to-present visuals to help you act with confidence.
Stars
EXXUA (Gepirone ER) Commercial Launch
As of late 2025, EXXUA (gepirone ER) is Aytu’s primary Star after its Q4 2025 U.S. launch, targeting the $22 billion major depressive disorder market; early 2026 forecasts model peak sales of $800M–$1.2B by 2030 under base-case uptake assumptions.
EXXUA is first-in-class selective serotonin 5HT1a receptor agonist and reportedly avoids common SSRI/SNRI sexual dysfunction; analysts expect 30%+ CAGR in initial five years but note a heavy upfront marketing spend of $80M–$150M for national rollout.
Pediatric Portfolio Growth Initiatives
The Pediatric Portfolio, led by Karbinal ER and fluoride-based vitamins, moved into Star status by mid-2025 with revenue growth up to 77% YoY and estimated 2025 sales of ~$48M, driven by a return-to-growth plan that restored payer coverage and expanded sales rep reach from 120 to 220 territories.
Aytu RxConnect Platform Expansion
The proprietary RxConnect patient-access platform is a Star: it raised Aytu Biopharma’s prescription fulfillment rate to ~92% and cut patient out-of-pocket costs by 28% in 2024, driving a 35% CAGR in Rx volume across core brands.
By late 2025 RxConnect optimizes brand economics—lowering cost-per-prescription by an estimated $14 and boosting gross-to-net recovery—giving Aytu a clear edge in telehealth and digital pharmacy growth.
Ongoing $8–10M annual investments are needed to scale RxConnect as Aytu integrates new products like EXXUA into commercial ops and target an additional 50% prescription volume lift over 2026–2027.
Adzenys XR-ODT Market Leadership
Adzenys XR-ODT retained leadership in ADHD after 2024 stimulant shortages, with Aytu reporting double-digit sequential revenue growth through 2025 and a reset baseline that recovered market share versus peers.
Orally disintegrating tablet formulation drove uptake and higher adherence; product still needs sustained promotional spend to defend share against generics and branded competitors in a crowded market.
- Double-digit sequential revenue growth in 2025
- Recovered baseline post-2024 shortages
- ODT formulation boosts adherence and differentiation
- Requires ongoing promotion vs generics/branded rivals
Strategic CNS Sales Force Leverage
Aytu’s specialized Central Nervous System sales force is a Star unit, driving rapid adoption of new and existing therapies across an expanding prescriber network and helping capture share in MDD and ADHD.
The team was a primary driver of a 32% total revenue surge in fiscal 2025, showing high productivity in a growing therapeutic segment while requiring heavy investment in training and compensation to sustain growth.
- 32% revenue growth FY2025
- High prescriber adoption rates
- Significant training & comp costs
- Critical for MDD and ADHD market share
EXXUA launch fuels $800M–$1.2B peak; Pediatric +77%, RxConnect cuts costs, CNS +32%
Stars: EXXUA (launched Q4 2025) projected peak sales $800M–$1.2B by 2030; Pediatric portfolio 2025 sales ~$48M (+77% YoY); RxConnect drives 92% fulfillment, 28% lower OOP, saves ~$14 per script; CNS sales force drove 32% revenue growth FY2025.
| Asset | 2025 | Key metric |
|---|---|---|
| EXXUA | Launched Q4 2025 | Peak $800M–$1.2B |
| Pediatric | $48M | +77% YoY |
| RxConnect | 92% fill | -28% OOP; -$14/script |
| CNS sales | FY2025 | +32% rev |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Aytu’s portfolio with strategic actions for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Aytu BCG Matrix placing each product in a quadrant for quick portfolio decisions.
Cash Cows
ADHD Portfolio Revenue Stability
The ADHD portfolio, led by Adzenys (amphetamine HFA) and Cotempla (methylphenidate XR), is Aytu’s primary Cash Cow, delivering 57.6 million dollars in net revenue for fiscal 2025 and funding new initiatives.
Despite a mature, competitive ADHD market, these brands produce steady cash flow used to support the EXXUA launch and ongoing R&D spend.
The portfolio’s maturity allows Aytu to milk consistent adjusted EBITDA, which reached 9.2 million dollars for the full year 2025, underpinning capital allocation decisions.
Cotempla XR-ODT Market Position
Cotempla XR-ODT holds a solid niche in pediatric ADHD for long-acting methylphenidate in an orally disintegrating tablet, capturing about 12% of the pediatric methylphenidate ODT market in 2025 per IQVIA data.
As a mature brand with strong prescriber loyalty, promotional spend is ~35% lower than Aytu’s 2024 average for new launches, supporting higher gross margins near 68% in FY 2025.
Its steady sales—roughly $28M in revenue in the trailing twelve months to Q3 2025—helped Aytu record seven consecutive quarters of positive adjusted EBITDA through Q3 2025.
Poly-Vi-Flor and Tri-Vi-Flor Vitamin Lines
Poly-Vi-Flor and Tri-Vi-Flor are Cash Cows in Aytu’s Pediatric portfolio, selling in a mature U.S. market with ~5–7% annual volume decline but stable unit margins near 40% as of FY2024.
They keep steady cash flow—estimated $8–10M annual EBITDA in 2024—thanks to pediatrician brand recognition and low marketing spend (<2% of sales).
Manufacturing Cost Optimization
Following the 2024 closure of Aytu's Texas manufacturing facility and shift to contract manufacturing, the company cut fixed overhead by about $12–15 million annually, turning supply chain into a cash-generating asset by 2025.
Reduced cost of goods sold boosted gross margin on mature products from ~28% in 2023 to about 38% in 2025, freeing cash for R&D and commercial growth.
Operational efficiencies now serve as a cash cow, funneling roughly $10–13 million in annual free cash flow into high-growth areas.
- $12–15M overhead saved
- Gross margin +10pts (28%→38%)
- $10–13M added free cash flow
Established Payer and Distribution Networks
Aytu’s established payer contracts and national distribution reach act as cash cows, delivering steady margins from mature products such as Adzenys; in 2025 these channels contributed roughly 60–65% of product revenue and stabilized cash flow.
By 2025 the company tightened gross-to-net leakage, boosting net realizations by ~4–6 percentage points versus 2022, so a larger share of each dollar from mature SKUs drops to operating profit.
This logistics and reimbursement backbone needs low incremental capex—estimated at under 5% of revenue annually—while underpinning overall liquidity and funding for growth programs.
- 2025 share: 60–65% revenue from mature products
- Gross-to-net improvement: +4–6 pts vs 2022
- Maintenance capex: <5% of revenue
Restructuring lifts margins to ~38%, driving $10–13M FCF with $57.6M ADHD revenue
The ADHD duo (Adzenys, Cotempla) and Pediatric vitamins (Poly‑Vi‑Flor, Tri‑Vi‑Flor) generated stable cash: $57.6M net revenue and $9.2M adjusted EBITDA for ADHD in FY2025; vitamins ~ $8–10M EBITDA in 2024; cost cuts saved $12–15M, boosting gross margin ~+10 pts to ~38% by 2025 and adding $10–13M free cash flow.
| Metric | Value (FY2025) |
|---|---|
| ADHD revenue | $57.6M |
| ADHD adj. EBITDA | $9.2M |
| Vitamins EBITDA | $8–10M (2024) |
| Overhead saved | $12–15M |
| Gross margin (mature) | ~38% (+10 pts) |
| Free cash flow boost | $10–13M |
What You’re Viewing Is Included
Aytu BCG Matrix
The file you're previewing is the exact BCG Matrix report you'll receive after purchase—no watermarks, no demo text, just the fully formatted, analysis-ready document designed for strategic use.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
See the Bigger Picture
Aytu’s BCG Matrix preview highlights where its core products may sit across Stars, Cash Cows, Dogs, and Question Marks, offering a quick read on growth potential and portfolio risks; the full report expands this into quadrant-level placements, market-share drivers, and prioritized strategic moves. Purchase the complete BCG Matrix for a detailed Word report plus an editable Excel summary that delivers data-backed recommendations, resource allocation guidance, and ready-to-present visuals to help you act with confidence.
Stars
EXXUA (Gepirone ER) Commercial Launch
As of late 2025, EXXUA (gepirone ER) is Aytu’s primary Star after its Q4 2025 U.S. launch, targeting the $22 billion major depressive disorder market; early 2026 forecasts model peak sales of $800M–$1.2B by 2030 under base-case uptake assumptions.
EXXUA is first-in-class selective serotonin 5HT1a receptor agonist and reportedly avoids common SSRI/SNRI sexual dysfunction; analysts expect 30%+ CAGR in initial five years but note a heavy upfront marketing spend of $80M–$150M for national rollout.
Pediatric Portfolio Growth Initiatives
The Pediatric Portfolio, led by Karbinal ER and fluoride-based vitamins, moved into Star status by mid-2025 with revenue growth up to 77% YoY and estimated 2025 sales of ~$48M, driven by a return-to-growth plan that restored payer coverage and expanded sales rep reach from 120 to 220 territories.
Aytu RxConnect Platform Expansion
The proprietary RxConnect patient-access platform is a Star: it raised Aytu Biopharma’s prescription fulfillment rate to ~92% and cut patient out-of-pocket costs by 28% in 2024, driving a 35% CAGR in Rx volume across core brands.
By late 2025 RxConnect optimizes brand economics—lowering cost-per-prescription by an estimated $14 and boosting gross-to-net recovery—giving Aytu a clear edge in telehealth and digital pharmacy growth.
Ongoing $8–10M annual investments are needed to scale RxConnect as Aytu integrates new products like EXXUA into commercial ops and target an additional 50% prescription volume lift over 2026–2027.
Adzenys XR-ODT Market Leadership
Adzenys XR-ODT retained leadership in ADHD after 2024 stimulant shortages, with Aytu reporting double-digit sequential revenue growth through 2025 and a reset baseline that recovered market share versus peers.
Orally disintegrating tablet formulation drove uptake and higher adherence; product still needs sustained promotional spend to defend share against generics and branded competitors in a crowded market.
- Double-digit sequential revenue growth in 2025
- Recovered baseline post-2024 shortages
- ODT formulation boosts adherence and differentiation
- Requires ongoing promotion vs generics/branded rivals
Strategic CNS Sales Force Leverage
Aytu’s specialized Central Nervous System sales force is a Star unit, driving rapid adoption of new and existing therapies across an expanding prescriber network and helping capture share in MDD and ADHD.
The team was a primary driver of a 32% total revenue surge in fiscal 2025, showing high productivity in a growing therapeutic segment while requiring heavy investment in training and compensation to sustain growth.
- 32% revenue growth FY2025
- High prescriber adoption rates
- Significant training & comp costs
- Critical for MDD and ADHD market share
EXXUA launch fuels $800M–$1.2B peak; Pediatric +77%, RxConnect cuts costs, CNS +32%
Stars: EXXUA (launched Q4 2025) projected peak sales $800M–$1.2B by 2030; Pediatric portfolio 2025 sales ~$48M (+77% YoY); RxConnect drives 92% fulfillment, 28% lower OOP, saves ~$14 per script; CNS sales force drove 32% revenue growth FY2025.
| Asset | 2025 | Key metric |
|---|---|---|
| EXXUA | Launched Q4 2025 | Peak $800M–$1.2B |
| Pediatric | $48M | +77% YoY |
| RxConnect | 92% fill | -28% OOP; -$14/script |
| CNS sales | FY2025 | +32% rev |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Aytu’s portfolio with strategic actions for Stars, Cash Cows, Question Marks, and Dogs.
Customizable Excel Spreadsheet
One-page Aytu BCG Matrix placing each product in a quadrant for quick portfolio decisions.
Cash Cows
ADHD Portfolio Revenue Stability
The ADHD portfolio, led by Adzenys (amphetamine HFA) and Cotempla (methylphenidate XR), is Aytu’s primary Cash Cow, delivering 57.6 million dollars in net revenue for fiscal 2025 and funding new initiatives.
Despite a mature, competitive ADHD market, these brands produce steady cash flow used to support the EXXUA launch and ongoing R&D spend.
The portfolio’s maturity allows Aytu to milk consistent adjusted EBITDA, which reached 9.2 million dollars for the full year 2025, underpinning capital allocation decisions.
Cotempla XR-ODT Market Position
Cotempla XR-ODT holds a solid niche in pediatric ADHD for long-acting methylphenidate in an orally disintegrating tablet, capturing about 12% of the pediatric methylphenidate ODT market in 2025 per IQVIA data.
As a mature brand with strong prescriber loyalty, promotional spend is ~35% lower than Aytu’s 2024 average for new launches, supporting higher gross margins near 68% in FY 2025.
Its steady sales—roughly $28M in revenue in the trailing twelve months to Q3 2025—helped Aytu record seven consecutive quarters of positive adjusted EBITDA through Q3 2025.
Poly-Vi-Flor and Tri-Vi-Flor Vitamin Lines
Poly-Vi-Flor and Tri-Vi-Flor are Cash Cows in Aytu’s Pediatric portfolio, selling in a mature U.S. market with ~5–7% annual volume decline but stable unit margins near 40% as of FY2024.
They keep steady cash flow—estimated $8–10M annual EBITDA in 2024—thanks to pediatrician brand recognition and low marketing spend (<2% of sales).
Manufacturing Cost Optimization
Following the 2024 closure of Aytu's Texas manufacturing facility and shift to contract manufacturing, the company cut fixed overhead by about $12–15 million annually, turning supply chain into a cash-generating asset by 2025.
Reduced cost of goods sold boosted gross margin on mature products from ~28% in 2023 to about 38% in 2025, freeing cash for R&D and commercial growth.
Operational efficiencies now serve as a cash cow, funneling roughly $10–13 million in annual free cash flow into high-growth areas.
- $12–15M overhead saved
- Gross margin +10pts (28%→38%)
- $10–13M added free cash flow
Established Payer and Distribution Networks
Aytu’s established payer contracts and national distribution reach act as cash cows, delivering steady margins from mature products such as Adzenys; in 2025 these channels contributed roughly 60–65% of product revenue and stabilized cash flow.
By 2025 the company tightened gross-to-net leakage, boosting net realizations by ~4–6 percentage points versus 2022, so a larger share of each dollar from mature SKUs drops to operating profit.
This logistics and reimbursement backbone needs low incremental capex—estimated at under 5% of revenue annually—while underpinning overall liquidity and funding for growth programs.
- 2025 share: 60–65% revenue from mature products
- Gross-to-net improvement: +4–6 pts vs 2022
- Maintenance capex: <5% of revenue
Restructuring lifts margins to ~38%, driving $10–13M FCF with $57.6M ADHD revenue
The ADHD duo (Adzenys, Cotempla) and Pediatric vitamins (Poly‑Vi‑Flor, Tri‑Vi‑Flor) generated stable cash: $57.6M net revenue and $9.2M adjusted EBITDA for ADHD in FY2025; vitamins ~ $8–10M EBITDA in 2024; cost cuts saved $12–15M, boosting gross margin ~+10 pts to ~38% by 2025 and adding $10–13M free cash flow.
| Metric | Value (FY2025) |
|---|---|
| ADHD revenue | $57.6M |
| ADHD adj. EBITDA | $9.2M |
| Vitamins EBITDA | $8–10M (2024) |
| Overhead saved | $12–15M |
| Gross margin (mature) | ~38% (+10 pts) |
| Free cash flow boost | $10–13M |
What You’re Viewing Is Included
Aytu BCG Matrix
The file you're previewing is the exact BCG Matrix report you'll receive after purchase—no watermarks, no demo text, just the fully formatted, analysis-ready document designed for strategic use.
